Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Clinical-development physician is responsible for to drop a secondary in a company, using a CMC site change mid-review with advisory-committee question list that exposes a weak secondary endpoint as the only working extract. A competitor label that just got a narrower indication is what reset the timeline for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a competitor label that just got a narrower indication for clinical-development physician. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to drop a secondary turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a competitor label that just got a narrower indication. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (advisory-committee question list that exposes a weak secondary endpoint after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option advisory-committee question list that exposes a weak secondary endpoint can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for clinical-development physician in a company with a CMC site change mid-review.